Navigation Links
Biopure Receives Notice of Nasdaq Delisting
Date:6/30/2009

CAMBRIDGE, Mass., June 30 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced that it has received notice from The Nasdaq Stock Market, by letter dated June 24, 2009, that it is out of compliance with the Nasdaq Marketplace Rules and its common stock may be delisted. The notice stated that the company no longer meets the minimum of $2,500,000 in stockholders' equity for continued listing on the Nasdaq Capital Market.

Nasdaq advised that the company has 15 calendar days to submit a plan to regain compliance. If such plan is accepted, Nasdaq may grant an extension of up to 105 days from the date of notification to regain compliance. If the Company is unable to regain compliance its common stock will be delisted. The company does not intend to submit a plan to regain compliance.

Biopure Corporation

Biopure Corporation develops and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues. The company has limited remaining cash. It is exploring the potential sale of some, substantially all, or all of its assets, and is evaluating liquidation.

    Contact:  Zaf Zafirelis
              Biopure Corporation
              (617) 234-6500
              IR@biopure.com


'/>"/>
SOURCE Biopure Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Biopure Announces Reverse Stock Split
2. Biopures Stock Symbol Reverts to BPUR
3. Biopure Announces Closing of $14.9 Million Financing
4. Four Abstracts by Biopure and Collaborating Scientists Accepted for Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
5. Biopure Announces 2007 Fourth Quarter and Year-End Financial Results
6. Biopure Receives Comment Letter From U.K. Regulatory Body on Marketing Application for Hemopure(R)
7. Biopure Reaffirms Strategy Following Recent NIH/FDA Workshop
8. Biopure Receives Extension of Time to Regain NASDAQ Listing Compliance
9. Agency Takes Adverse Decision to Biopures Product Registration in South Africa
10. Biopure Sues National Institutes of Health Official
11. Biopure Submits IND Application for Proposed Clinical Trial in Patients with Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... Yisrayl Hawkins, ... focuses on Bible Prophecy concerning this present generation. Yisrayl makes an astounding statement ... current generation. He explains that the Bible details the current times so plainly ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations to Head Over Heels’ ... February 12th. Ms. Esparza qualified into this prestigious status after winning the ... Las Vegas, Nevada. Frida is one of approximately 25 gymnasts in the nation ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... return to the La Gorce Country Club in Miami Beach to host its ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, a ... content marketing, social media management, corporate communications, SEO and cause marketing, is opening ... in nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding its ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... and uncertainty in clinical trials, today announced that Premier Research, a leading clinical ... solution. , Clinical trials are becoming increasingly complex, due in part to an ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... -- ITL Limited, ( ASX: ITD ), an innovative diversified healthcare ... ended 31 December 2016 compared with the previous corresponding period. A ... here . Highlights ... Earnings per share of 2.2 cents (Dec 2015: 1.2 ... $15.7m; up 11%) Profit before tax of $2.12m ...
(Date:2/23/2017)... Research and Markets has announced the addition of the "Oesophageal ... their offering. ... The latest research Oesophageal Cancer Drugs Price Analysis and Strategies - ... Cancer market. The research answers the following questions: ... Oesophageal Cancer and their clinical attributes? How are they positioned in ...
(Date:2/23/2017)... VALLEY COTTAGE, New York , February 23, 2017 ... to health implications arising from increasing caseload for varicose ... cases recorded across the globe are prompting the adoption ... A latest study on global endovenous laser therapy ... growing attention towards aftereffects of lifestyle choices and consequences ...
Breaking Medicine Technology: